Retatrutide
Retatrutide is a triple-hormone receptor agonist that interacts with three major metabolic pathways: GLP-1, GIP, and glucagon receptors. Experimental research indicates that concurrent activation of these receptors modulates energy metabolism, nutrient signaling, and glucose homeostasis. Investigations in preclinical and early-phase studies have observed combined influences on body composition, glycemic balance, hepatic lipid metabolism, and cardiovascular biomarkers.
Select Dosage
Purchase Options
Bulk Discounts
The information provided is for educational and informational purposes only and should not be interpreted as medical advice. All products described herein are intended strictly for laboratory and research use. They are not approved for human or veterinary administration, and should only be handled by qualified professionals in controlled research environments. Any clinical research must be conducted under the supervision and approval of an Institutional Review Board (IRB), and all preclinical studies must adhere to Institutional Animal Care and Use Committee (IACUC) guidelines in accordance with the Animal Welfare Act (AWA). Users are encouraged to conduct their own due diligence, referencing trusted scientific sources and verifying all information independently before making any purchasing or experimental decisions.
⚠️ Notice: All products are sold for laboratory and research purposes only. They are not intended for diagnostic, therapeutic, or personal use under any circumstances.
Retatrutide
Overview
Retatrutide is a triple-hormone receptor agonist that interacts with three major metabolic pathways: GLP-1, GIP, and glucagon receptors. Experimental research indicates that concurrent activation of these receptors modulates energy metabolism, nutrient signaling, and glucose homeostasis. Investigations in preclinical and early-phase studies have observed combined influences on body composition, glycemic balance, hepatic lipid metabolism, and cardiovascular biomarkers. As of 2025, Retatrutide remains under Phase 3 clinical evaluation; all findings here refer to preclinical and published research contexts.
Mechanistic Insights
GLP-1 Receptor Activation
- Observed modulation of insulin sensitivity, appetite regulation, and gastric-emptying rate in metabolic models.
- Reported influence on central satiety centers within the hypothalamic arcuate nucleus.
- Linked to slower glucose absorption and improved postprandial glycemic dynamics in controlled experiments.
GIP Receptor Activation
- Investigated for its role in enhancing insulin response and lipid-handling pathways.
- Observed activation of lipogenic and oxidative genes involved in energy balance.
- May contribute to incretin synergy when co-activated with GLP-1 signaling.
Glucagon Receptor Activation
- Preclinical data suggest increased energy expenditure, lipolysis, and hepatic fat turnover through glucagon-pathway stimulation.
- Observed effects on thermogenic tissues and hepatic mitochondrial metabolism, supporting fat oxidation and substrate switching.
Preclinical Research Findings
3.1 Metabolic and Weight-Regulation Models
- Animal studies have reported sustained body-weight reduction and altered energy balance following triple-receptor activation (Jastreboff 2023).
- Observed outcomes include decreased caloric intake, elevated fat oxidation, and maintained energy expenditure, with involvement of central appetite circuits and peripheral lipid mobilization pathways.
3.2 Glucose Regulation and Insulin Sensitivity
- Retatrutide has been investigated for its potential to influence glucose homeostasis through incretin pathways; preclinical metabolic models demonstrate improved glucose uptake, enhanced insulin sensitivity, and modulation of hepatic glucose output (Frias 2023).
3.3 Hepatic Lipid and Steatosis Research
- Magnetic-resonance and molecular analyses report substantial reduction of hepatic- lipid content in experimental settings (Loomba 2024), with normalization of liver-fat indices and improved mitochondrial oxidative signatures.
- Associated with decreased markers of hepatic inflammation and fibrogenic activity; all findings remain non-clinical.
3.4 Cardiometabolic and Lipid Studies
- Observed modulation of cholesterol and triglyceride levels in metabolic-animal models (Lilly 2023), with reported reductions in inflammatory biomarkers including CRP and IL-6.
- Findings suggest favorable shifts in lipid transport and vascular function; mechanisms remain under exploration, with preclinical assessments noting maintenance of lean mass and preferential fat mobilization.
3.5 Appetite and Satiety Regulation
- Neurobehavioral models show decreased hypothalamic hunger signaling upon GLP-1/GIP receptor co-activation (Jastreboff 2023), with observed delay in gastric emptying and prolonged postprandial satiety.
3.6 Energy Expenditure and Fat Oxidation
- Preclinical findings demonstrate glucagon-receptor–driven activation of brown-adipose thermogenesis and resting energy expenditure (Sainsbury 2024), with enhanced hepatic and adipose lipolysis supporting sustained fatty-acid utilization.
- Experimental data suggest mitigation of metabolic slowdown during caloric restriction phases.
3.7 Longevity and Inflammation-Pathway Research
- Transcriptomic profiling reveals activation of AMPK-related and mitochondrial biogenesis pathways, with reported declines in systemic oxidative and inflammatory gene expression under metabolic-stress conditions.
- Investigators note potential research relevance for metabolic-healthspan and cellular homeostasis; interpretations remain exploratory.
Research References
- Jastreboff A.M. et al. (2023). Triple-Hormone Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine — Phase 2 results indicating up to 24.2% mean weight loss over 48 weeks.
- Frias J.P. et al. (2023). Phase 2 Evaluation of Retatrutide in Type 2 Diabetes Mellitus. Significant HbA1c and fasting-glucose improvements.
- Loomba R. et al. (2024). Normalization of Hepatic Fat with Retatrutide in NAFLD/MASLD Patients.
- Lilly Clinical Development Report (2023). TRIUMPH and SURPASS Program Findings: Cardiometabolic and Appetite Outcomes.
- Sainsbury A. et al. (2024). Preclinical Validation of Glucagon-Receptor–Driven Energy Expenditure Increases.
- ClinicalTrials.gov Identifiers: NCT04881760, NCT06383390, NCT06859268 — Ongoing long- term outcome studies on weight, cardiovascular, and safety parameters.
Product Specifications
C₂₀₁H₃₂₄N₄₆O₆₈
4470.1 g/mol
2381089-83-2
LY3437943; Triple GIP/GLP-1/Glucagon Receptor Agonist
Lyophilized powder
Keep refrigerated upon reconstitution
Soluble in sterile water and 0.9% NaCl solution
Research-use only. All information summarizes preclinical and in-vitro studies and is not intended for diagnostic, therapeutic, or personal use.
Frequently Asked Questions
Get answers to common questions about Retatrutide and our research peptides.
Have Questions About Retatrutide?
Get in touch with our research team for detailed information and support.